AMGN logo Amgen +
Amgen
+

Amgen Overview

Company: Amgen
CEO: Robert A. Bradway
Founded: Apr 8, 1980
Symbol: AMGN
Exchange: NASDAQ
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's productslude Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen serves healthcare providers,luding physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics and Plexium Amgen wasorporated in 1980 and is headquartered in Thousand Oaks, California.

Continue reading...

Amgen (AMGN)

  • Stock Price
  • Volume
336.79 +103.21 +44.19%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Amgen annual revenue was $36.75 B in 2025.

Net Income

Amgen annual net income was $7.71 B in 2025.

Employees

Amgen annual employee count was 31,500 in 2025.

Revenue by Segment

Amgen’s revenue by segment: Aranesp: $1.39 B, BLINCYTO: $1.56 B, ENBREL: $2.23 B, EVENITY: $2.10 B, KRYSTEXXA: $1.34 B, Nplate: $1.52 B, Otezla: $2.27 B, Other Products: $7.26 B, Product and Service, Other: $1.60 B, Prolia: $4.41 B, Repatha: $3.02 B, TEPEZZA: $1.90 B, TEZSPIRE: $1.48 B, Vectibix: $1.18 B and XGEVA: $2.08 B in 2025.

Revenue by Region

Amgen’s revenue by region: Non-US: $10.33 B and UNITED STATES: $26.42 B in 2025.

Executive Salary

Robert A. Bradway Chief Executive Officer and President, at Amgen, m...

Revenue per Employee

Amgen revenue per employee was $1.17 M in 2025.

Profit per Employee

Amgen profit per employee was $244.79 K in 2025.

Income Statement

Operating Income

Amgen annual operating income was $14.89 B in 2025.

Research & Development

Amgen annual research & development expense was $7.27 B in 2025.

Tax Rate (%)

Amgen annual Tax Rate was 14.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Amgen annual total assets was $90.59 B in 2025.

Total Liabilities

Amgen annual total liabilities was $81.93 B in 2025.

Capital Expenditure

Amgen annual capital expenditures was -$1.86 B in 2025.

Ratios

Return on Equity (ROE)

Amgen annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Amgen annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Amgen annual debt to equity was 630.68% in 2025.

Profitability

Gross Profit Margin (%)

Amgen annual gross profit margin was 82.52% in 2025.

Operating Income Margin (%)

Amgen annual operating income margin was 40.52% in 2025.

Net Income Margin (%)

Amgen annual net income margin was 20.99% in 2025.

Earning Per Share

Amgen annual earning per share was $14.33 in 2025.

EBITDA

Amgen annual EBITDA was $17.13 B in 2025.

Free Cash Flow (FCF)

Amgen annual free cash flow(FCF) was $8.10 B in 2025.

Valuation

Enterprise value

Amgen annual enterprise value was - in 2025.

Enterprise value to Revenue

Amgen annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Amgen annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Amgen founded?

Amgen was founded on Apr 8, 1980, which makes the company 46 years old.

Sign up for free to view

Who is the CEO of Amgen?

Robert A. Bradway is the CEO of Amgen.

What industry and sector is Amgen in?

Amgen operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Amgen's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000318154
  • SIC (Standard Industrial Classification): 2836
  • ISIN (International Securities Identification Number): US0311621009

Sign up for free to view

How many employees does Amgen have?

Amgen has 31,500 employees.

What is the revenue of Amgen?

In fiscal year 2025, Amgen generated a revenue of $36.75 Billion.

What is the net income of Amgen?

In fiscal year 2025, Amgen reported a net income of $7.71 Billion.

What is Amgen's biggest product segment?

Other Products is Amgen's biggest product segment, representing 20.55% of its total revenue.

When was Amgen listed on the stock exchange?

Amgen went public on Jun 17, 1983, through its Initial Public Offering (IPO), and it has been 42 years since then.

Sign up for free to view

What is the ticker symbol of Amgen, and where is it listed?

Amgen's ticker symbol is AMGN, and the company is listed on the NASDAQ stock market exchange.

What is Amgen's current stock price?

Amgen's current stock price is $336.78 as of May 30, 2026.

What is Amgen's market capitalization?

As of , Amgen's market cap is .

What is Amgen's ranking in the world?

Ranked #9among 2,804 companies based on market cap.

Who are the top competitors of Amgen?

Competitors of Amgen include Eli Lilly and Company, Johnson & Johnson and AbbVie, and more.

Related company

Submit feedback to Bullfincher